Table 3 Impact of the bladder filling control on plan dosimetry of rectum cancer adaptive treatments
| Â | Adapted plans optimized on \({\text{MRI}}_{{\text{i}}}\) | Adapted plan recalculated on \({\text{MRI}}_{{\text{f}}}\) | t student |
|---|---|---|---|
Reference value Median (range) | % difference | p | |
Adapted plans | |||
 Number | 109 |  |  |
PTV | |||
 Volume (cc) | 648.5 (419.4–1016.3) |  |  |
 \(V_{{{\text{Dpre}}}}\) (%) | 95.76 (95.02–96.80) | < 0.65 | > 0.05 |
 \({\text{D}}_{{0.5{\text{cc}}}}\) (Gy) | 26.54 (26.23–27.90) | < 0.50 | > 0.05 |
Bladder | |||
 Volume (cc) | 154.8 (110.4–238.6) |  |  |
 \({\text{D}}_{{0.5{\text{cc}}}}\) (Gy) | 24.54 (17.61–26.60) | < 0.50 | > 0.05 |
 \({\text{D}}_{{15{\text{cc}}}}\) (Gy) | 13.96 (7.41–21.02) | < 0.15 | > 0.05 |
Small bowel | |||
 \({\text{D}}_{{0.5{\text{cc}}}}\) (Gy) | 23.72 (17.32–27.55) | < 0.45 | > 0.05 |
 \({\text{D}}_{{5{\text{cc}}}}\) (Gy) | 19.32 (18.55–21.99) | < 0.44 | > 0.05 |
 \({\text{D}}_{{10{\text{cc}}}}\) (Gy) | 17.31 (15.10–18.95) | < 0.33 | > 0.05 |
Femoral heads | |||
 \({\text{D}}_{{10{\text{cc}}}} \left( {{\text{Gy}}} \right)\) | 11.56 (10.51–14.61) | < 0.10 | > 0.05 |